NHS Bath and North East Somerset, Swindon and Wiltshire CCG Royal United Hospitals Bath NHS Foundation Trust Great Western Hospitals NHS Foundation Trust Salisbury NHS Foundation Trust
There are no shared care agreements available for ENT.
Self-care
Many of the products in this chapter are available for purchase over-the-counter, and patients are encouraged to self-care, with the support of their community pharmacist, in the first instance.
Second line for the treatment of allergic rhinitis
Licensed for nasal polyps.
Fluticasone furoate
(Nasal spray)
Second Choice
Fluticasone furoate nasal spray, 27.5 micrograms per spray
Second line for the treatment of allergic rhinitis
Fluticasone Propionate
(nasal drops)
Third Choice
Nasal drops 400 micrograms/unit dose
Only for the treatment of nasal polyps and associated symptoms of nasal obstruction.
Only to be used 3rd line as per the Local allergic rhinitis guidance (see top of this section for guidance links) March 2018
Fluticasone + Azelastine
(Nasal spray)
Third Choice
Azelastine 137 micrograms and Fluticasone propionate 50 micrograms per actuation
Only to be used 3rd line as per the local allergic rhinitis guidance
Betamethasone Sodium Phosphate 0.1%
(nasal drops)
Formulary
5ml nasal drops
....
Non Formulary Items
Flunisolide
(Syntaris®)
Non Formulary
Fluticasone Propionate
(Nasofan®)
Non Formulary
Triamcinolone Acetonide
(Nasacort®)
Non Formulary
Key
Notes
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Restricted Drug
Unlicensed
Display tracking information
Link to adult BNF
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
CCG
High Cost Drug Approval System
Traffic Light Status Information
Status
Description
RED - Hospital only – to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment.
Amber medicines are considered suitable for GP prescribing following specialist initiation or recommendation.
Shared Care - these medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.
These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations.
Suitable for patient to be directed to buy themselves
Not currently used. We intend to include this TLS in future to highlight where a decision to use this medicine is under review.
(In use from Oct 2020) Used where a decision has been made by the BSW APC not to routinely commission this preparation for its licensed indications. Do not prescribe.
Not currently used. We intend to include this TLS in future to highlight where this medicine and indication is ONLY available through a Specialist Centre according to a NICE Highly Specialised Technology or NHSE Specialised Commission Circular / Policy.
